OUR ENTERPRISE
OUR ENTERPRISEFounded in 2013, Zhejiang Wenda Medical Technology Co., Ltd. is a high-tech enterprise specializing in new drug discovery and development. At present, the company is located in No. 201, 2nd Floor, Dongsheng Huigu Building 7, Kehai Avenue 1299, Anchang District, Shaoxing City, Zhejiang, China. The products under development include new drugs for a variety of cancers and autoimmune diseases, and a number of products have entered phase I, phase II and phase III trials.
管線
PIPELINE浙江文達醫藥以滿足臨床需求為導向來開發自己擁有全球知識產權的高質量化合物。
1：NHWD-870 晚期癌癥研究進展，目前在臨床二期。
2：WD-890 銀屑病，紅斑狼瘡，腸炎等適應癥，目前在臨床三期。
3: WD-910 多發性硬化癥，癡呆癥，目前在臨床一期。
4：WD-920 漸凍癥，帕金森。
5：WD-930 腫瘤。
6：WD-940
腫瘤。
Zhejiang Wenda develops its own high-quality compounds with global intellectual
property.
1. NHWD-870 Advanced cancer, in phase II.
2. WD-890 Indications such as psoriasis, lupus erythematosus and enteritis, etc, in phase III.
3. WD-910 Multiple sclerosis, dementia，in phase I.
4. WD-920 ALS, Parkinson`s disease.
5. WD-930 Advanced cancer.
6: WD-940 Advanced cancer.
| 項目名稱/代號 | 靶點 | 適應癥 | 研究進展 | NDA | |||||
|---|---|---|---|---|---|---|---|---|---|
| 化合物篩選 | 臨床前 | IND | I期 | II期 | III期 | ||||
| NHWD-870 | BET抑制劑 | 中線癌(NUT) | |||||||
| WD-890 | 外周TYK2(JH2)抑制劑 | 銀屑病 | |||||||
| 紅斑狼瘡 | |||||||||
| WD-910 | 中樞TYK2(JH2)抑制劑 | 多發性硬化癥，癡呆癥 | |||||||
| WD-920 | NA | 漸凍癥，帕金森 | |||||||
| WD-930 | NA | 腫瘤 | |||||||
| WD-940 | NA | HER2/HER2 20ins突變型腫瘤 | |||||||
